How does Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius work?

Pharmacotherapeutic group: electrolyte with carbohydrate.

What is the active ingredient in Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius?

Glucosum + Natrii chloridum (Glucosum, Natrii chloridum)

What pharmaceutical form is Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius available in?

Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius: Roztwór do infuzji (25 mg + 4,5 mg)/ml (dożylna)

Is Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius OTC or prescription only?

Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius requires a doctor's prescription.

What are the side effects of Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius?

The frequency of adverse events listed below is defined using the following convention: very common (≥1/10); common (≥1/100 to < 1/10); uncommon (≥1/1,000 to < 1/100); rare (≥1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data). Metabolism and nutrition disorders Not known: fluid and electrolyte disturbances including hypokalaemia, hypomagnesaemia and hypophosphataemia, hyperglycaemia, glycosuria. Hypokalaemia may complicate glucose infusions, e

Who should NOT take Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius?

Hyperglycaemia. Conditions of water excess

Does Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius interact with other medications?

Drugs leading to an increased vasopressin effect The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and increase the risk of hospital acquired hyponatraemia following inappropriately balanced treatment with i.v. fluids (see sections 4.2, 4.4 and 4.8). Drugs stimulating vasopressin release, e.g.: • Chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors, 3.4-methylenedioxy-N-methamphetamine, ifo

Can Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius be used during pregnancy?

It is particularly important to avoid maternal hyperglycaemia during intravenous glucose infusion in the perinatal period in view of the possibility of inducing neonatal hypoglycaemia. 5% Glucose Intravenous Infusion Solution should be administrated with special caution for pregnant women during labour particularly if administered in combination with oxytocin due to the risk of hyponatraemia (see sections 4.4, 4.5 and 4.8).

Who manufactures Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius?

Fresenius Kabi Polska Sp. z o.o. (Polska)

What ATC class does Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius belong to?

Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius: ATC B05BA03. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius — Description, Dosage, Side Effects | PillsCard

⚠️ Warnings

For single use only. Do not use unless the solution is clear and the container undamaged. Discard any unused solution. Any unused product or waste material should be disposed of in accordance with local requirements. COSINUS PVC and COSINUS bags: Remove the bag from the plastic overwrap. Remove the protector and connect by clamping to the administration set. COSINUS PVC -Perf and COSINUS-Perf bags : Remove the closed infusion system from the plastic peelable overwrap. Move the roller clamp down 1 cm before clamping the tubing. Prime the line : • Break the in-line cannula by flexing the tubing in one direction then the other • Fill the drip chamber with solution by squeezing the bag • Gradually open the flow regulator and prime the line fully • Clamp the tubing and connect to a luer as appropriate The flow rate must be checked regularly during infusion. Addition of medicinal products: • Confirm additive compatibility before use. • Clean the injection site using antiseptic solution. • Carefully introduce the sterile needle into the sterile chamber in the injection site, attach the needle to the container with the medicinal product, introduce the needle through the second membrane into the bag and inject the medicine. Carefully withdraw the needle. Mix thoroughly with the solution. Use immediately. Easyflex N and Easyflex + bags: • Remove the bag from the plastic overwrap. • Do not use needles or spikes to gain access to the needleless connector site. Connection of syringes to the needleless connector for the injection of a medicine or aspiration of solutions 1) Confirm additive compatibility before use. 2) Clean the injection site using antiseptic solution. 3) Attach the male luer-lock connector of the syringe with the bag's needleless connector by pushing in and twisting the syringe clockwise to secure the connection. 4) Aspirate the IV solution out of the bag, or inject the fluid or medicine into the bag. Mix thoroughly with the solution. Use immediately. 5) Disconnect the syringe from the needleless connection site by twisting anti- clockwise. 6) The needleless connection site closes automatically. 7) The needleless connection site can be reconnected several times by repeating steps 1 to 3. Connection of an IV giving set with a spike for the administration of an IV solution: Easyflex N: • Remove the protective cover (twist-off); • Connect the giving set to the bag by piercing the port and fully insert the giving set using a rotating movement. • Administer IV fluid or medicine. Easyflex +: • Remove the infusion site protector by breaking it; • Connect the giving set to the bag by piercing the port without rotating movement. • Administer IV fluid or medicine Connection of an IV giving set with a male luer-lock connector to the needleless connector for the administration of an IV solution Use the needleless connector to infuse an IV solution with a giving set fitted with a male luerlock connector. 1. Clean the injection site using antiseptic solution. Attach the male luer-lock connector of the 2. IV giving set with the female luer of the bag's needleless connection site by pushing in and twisting the set clockwise to secure the connection. 2. Administer IV fluid or medicine in the usual manner 3. Disconnect the giving set from the needleless connection site by twisting the luer-lock connection anti-clockwise. 4. The needleless connection site closes automatically and provides valve safety.

Glucosum 5% et Natrium chloratum 0,9% 1:1 Fresenius

User Reviews